



| HPAP | 083 | UNOS | | | |
|---|-------------------------------|--|------------------------------|---------------------------------------|--|
| Recovery OPO | Gift of Life Donor Program | Allocation Via | UPENN 🗵 | nPOD 🗆 | |
| Age (years) | 45 | DCD | YES 🗆 N | 0 🗆 | |
| Race | African American | DBD | YES 🗵 N | 0 🗆 | |
| Sex | M⊠ F□ | Admission to Cross Clamp | 119 Hours | Mins. | |
| ABO (Rh) | A1+ | Cross Clamp Time | 02/04/2021 | 03:11 | |
| BMI (Kg/m²) Weight (kg) Height (cm) | 35.62 112.6 177.8 | Cold Ischemia Time* | 8 Hours 22 Min. | | |
| Cause of Death | Anoxia | Preservation Solution | UW 🗵 H | тк□ | |
| Mechanism of Injury | Cardiovascular | Organs Recovered | Heart ⊠ Lung ⊠ Liver ⊠ | Kidney ⊠ Pancreas ⊠ Intestine □ | |
| Cardiac Arrest/Downtime | Yes ⊠ No □ | Intraoperative time lapse from liver to pancreas removal from the peritoneal cavity: | 1 Hours | 18 Mins. | |
| CPR / Time | Yes ⊠ 30 Minutes No □ | Organs Discarded | Heart Lung Liver Liver | Kidney Pancreas Intestine | |
| Total Est. Downtime | 30 Minutes | Blood Culture | No Growth | | |
| Date /Time of Admission | 01/30/2021 03:47 EST | PHS High Risk | YES □ NO ⊠ | | |
| | | Acute Lung Injury | No | | |
| | | | | | |

^{*}Cold Ischemia time is calculated from time of cross clamp to start of enzyme perfusion for islet isolation.

HPAP-083 Donor Summary



Medical History:

| | | Duration | Medications | Compliance | |
|--------------------|--|-----------------|-----------------------|------------|--|
| Type of Diabetes | T2DM | 2-3 years | Insulin | yes | |
| History of cancer | | | | | |
| CAD | | | | | |
| Hypertension | yes | 2-3 years | unknown | Yes | |
| Hyperlipidemia | | | | | |
| Autoimmune disease | | | | | |
| Family History | CAD ⊠ | Diabetes 🗆 | Auto immune disease 🗆 | Others: | |
| | | | | | |
| Surgical History: | None | | | | |
| | | | | | |
| | | | | | |
| Comments: | Family Hx: father and Uncle had CAD | | | | |
| | Social Hx: smoked 1 ppd cigarette x20 years, smoked Marijuana x 20 years | | | | |
| | Etoh Hx: 1 | -2 drinks per w | veek for adult life | | |

Hemodynamic Profile

| Average BP During Hospitalization (mmHg) | 134/73 | |
|--|------------|--------------------|
| Average Low BP During Hospitalization | 81/60 | Duration: 1-60 min |
| Average BP in OR (mmHg) | 150/70 | |
| Average Low BP in OR (mmHg) | 140/70 | Duration: 10 min |
| Average HR in OR (bpm) | 78 | |
| ABG-pH range | 7.08 – 7.5 | |

INTERVENTION

Blood Products/Meds Transfused Before Organ Recovery

| Product | Amount (ml) | Units | Total (ml) | |
|---------------------------|-------------|---|--------------------------------|--|
| Fresh Frozen Plasma | | | | |
| PRBCs | | | | |
| Platelets | | | | |
| Norepinephrine (Levophed) | | Avg dose 10 mcg/min started 5 days before organ | | |
| | | recovery | | |
| Vasopressin | | Avg dose 0.02 units/hr started 2 days before | | |
| | | organ recovery | | |
| Neo-Synephrine | | | | |
| Epinephrine | | Avg dose 2 mg/kg/r | nin started 1 day before organ | |
| | | recovery | | |
| Phenylephrine | | | | |
| Dopamine | | | | |

HPAP-083 Donor Summary



Blood Products/Meds Transfused Intraoperative

| Product | Amount (ml) | Units | Total (ml) |
|--------------------------------|-------------|--------------|------------|
| Fresh Frozen Plasma | | | |
| PRBCs | | | |
| Platelets | | | |
| Norepinephrine (Levophed) | | 8 mcg/kg/min | |
| Vasopressin | | | |
| Neo-Synephrine (phenylephrine) | | 40 mcg/hr | |
| Epinephrine | | | |
| Dopamine | | | |
| Heparin | | 30,000 | |

Initial Autoantibody Screening (nPOD): ELISA

Not performed for HPAP-T2D program

| GAD-65 | IA-2 |
|--------|------|
| ND | ND |

Confirmatory results: Radioimmuno Assay (RIA)

| | GAD-65 (unit/ml) | IA-2 (unit/ml) | Insulin AAB (unit/ml) | ZnT8 (unit/ml) |
|-----------------------|---------------------|-------------------|--------------------------|-------------------|
| Results | 0 | 0 | 0.000 | 0.002 |
| Cut-off values | 20 | 5 | 0.010 | 0.020 |

^{*}Sample obtained at time of organ recovery.

| | C-peptide (ng/ml) | Proinsulin | |
|---------|----------------------|------------|--|
| Results | 4.35 | | |

^{*}Sample obtained at time of organ recovery.

HLA (OPO)*

| 11111 | | | | | | | |
|----------|-----|----------|----|----------|------|------------|------------|
| Class 1 | Α | 23 | 29 | Class II | DR | 01 | 13 |
| | В | 07 | 45 | | DR51 | N-Negative | N-Negative |
| | С | 07 | 16 | | DR52 | 52 | 52 |
| | Bw4 | Negative | | | DR53 | N-Negative | N-Negative |
| | Bw6 | Positive | | | DQB1 | 03(7) | 05 |
| | | | | | DQA1 | 01 | 05 |
| | | | | | DPB1 | 01:01 | 17:01 |
| | | | | | | | |
| Comment: | | | | | | | |





Confirmatory HLA (UPENN)*

Not performed for HPAP-T2D program

| Class 1 | Α | | Class II | DRB1 | |
|---------|---|--|----------|------|--|
| | В | | | DRB3 | |
| | С | | | DRB4 | |
| | | | | DRB5 | |
| | | | | DQB1 | |
| | | | | DQA1 | |
| | | | | DPB1 | |
| | | | | DPA1 | |

^{*}HLA typing performed using NGS

Infectious Disease Serology

| | | Hemo/Plasma | Dilution Status |
|-----------------|--------------|-------------|-----------------|
| Test | Result | Qualified | Non-Qualified |
| EBV IgG | Positive | ✓ | - |
| EBV IgM | Negative | 1 | - |
| CMV | Positive | ✓ | - |
| HBcAb | Non Reactive | ✓ | - |
| HBsAg | Non Reactive | √ | - |
| HCV Ab | Non Reactive | ✓ | - |
| HIV I/II | Non Reactive | ✓ | - |
| Syphilis | Non Reactive | ✓ | - |
| Procleix Ultrio | | | - |
| Ultrio HBV | Non Reactive | ✓ | - |
| Ultrio HCV | Non Reactive | ✓ | - |
| Ultrio HIV | Non Reactive | √ | - |
| Toxoplasma Ab | Negative | √ | - |
| SARS-CoV-2 | Negative | ✓ | - |

HPAP-083 Donor Summary



Laboratory Panel

| | Initial | Peak | Terminal |
|-------------------------------|---------|------|----------|
| Na (mEq/L) (135-145) | 145 | 147 | 146 |
| Creatinine (<1.5) | 2.73 | 3.24 | 3.03 |
| Glucose (mg/dL) (60-150) | 345 | 345 | 210 |
| HbA1C% | 5 | | |
| Total bilirubin (0-1.0) | 0.2 | 0.7 | 0.7 |
| SGOT (AST) (0-40) | 125 | 562 | 88 |
| SGPT (ALT) (5-35) | 103 | 151 | 116 |
| Alkaline phosphatase (45-110) | 87 | 116 | 116 |
| Serum Amylase (23-851) | 48 | | |
| Serum Lipase (0-80) | 51 | | |
| WBC (THO/uL) (4.5-11.0) | 9.6 | 22.3 | 20 |
| Hgb (g/dL) (12-16) | 11.9 | 11.9 | 8.9 |
| Platelets (THO/uL) (150-350) | 272 | 349 | 259 |
| INR (<2.0) | 1 | 1.3 | 1.3 |

Urinalysis

| | 1 st | 2 nd | 3 rd | 4 th |
|---------|-----------------|-----------------|-----------------|-----------------|
| Glucose | 500 | 1000 | | |

Medications During Hospitalization

| | - | | |
|----------------------------|--|---------|--|
| Steroids** | | | |
| Diuretics | Mannitol 50 gms | | |
| T3 Protocol | | | |
| T4 Protocol* | Yes, 40 mcg/hr | | |
| Insulin** | 4-8 units insulin regular started 3 days before organ recovery | | |
| Antihypertensive | | | |
| Vasodilators | | | |
| DDAVP** | | | |
| Total parenteral nutrition | | | |
| Other | Amiodarone 150 mg, Ticagrelor 180 mg, | Specify | |
| | Cefepime 1 gm, Eptifibatide, Cleviprex | | |

^{*}T4 protocol: Levothyroxine, (20 mcgs), Solumedrol (2 gms,) Dextrose 50%, (1 amp), Regular Insulin (20u), Vasopressin (1 unit)

Mi Z, Novitzky D, Collins JF, Cooper D KC. The optimal hormonal replacement modality selection for multiple organ procurement from brain-dead organ donors. Clinical Epidemiology 2015:7 17-27.

^{**} Excluding T4 Protocol